Literature DB >> 17914261

Increase in beta-amyloid levels in cerebrospinal fluid of children with Down syndrome.

Hillevi Englund1, Göran Annerén, Jan Gustafsson, Ulrika Wester, Jens Wiltfang, Lars Lannfelt, Kaj Blennow, Kina Höglund.   

Abstract

BACKGROUND: Individuals with Down syndrome (DS) invariably develop Alzheimer's disease (AD) during their life span. It is therefore of importance to study young DS patients when trying to elucidate early events in AD pathogenesis. AIM: To investigate how levels of different amyloid-beta (Abeta) peptides, as well as tau and phosphorylated tau, in cerebrospinal fluid (CSF) from children with DS change over time. The first CSF sample was taken at 8 months and the following two samples at 20-40 and 54 months of age.
RESULTS: Individual levels of the Abeta peptides, as well as total Abeta levels in CSF increased over time when measured with Western blot. Tau in CSF decreased whereas there was no change in levels of phosphorylated tau over time.
CONCLUSION: The increasing levels of Abeta in CSF during early childhood of DS patients observed in this study are probably due to the trisomy of the Abeta precursor APP, which leads to an overproduction of Abeta. Despite the increased CSF concentrations of Abeta, there were no signs of an AD-indicating tau pattern in CSF, since the levels of total tau decreased and phosphorylated tau remained unchanged. This observation further strengthens the theory of Abeta pathology preceding tau pathology in AD. Copyright (c) 2007 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17914261     DOI: 10.1159/000109215

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  21 in total

1.  Overexpression of amyloid-β protein precursor induces mitochondrial oxidative stress and activates the intrinsic apoptotic cascade.

Authors:  Matthew G Bartley; Kristin Marquardt; Danielle Kirchhof; Heather M Wilkins; David Patterson; Daniel A Linseman
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

2.  Amyloid precursor protein (APP) processing genes and cerebrospinal fluid APP cleavage product levels in Alzheimer's disease.

Authors:  L M Bekris; N M Galloway; S Millard; D Lockhart; G Li; D R Galasko; M R Farlow; C M Clark; J F Quinn; J A Kaye; G D Schellenberg; J B Leverenz; P Seubert; D W Tsuang; E R Peskind; C E Yu
Journal:  Neurobiol Aging       Date:  2010-12-31       Impact factor: 4.673

3.  Amyloid beta peptide-(1-42) induces internalization and degradation of beta2 adrenergic receptors in prefrontal cortical neurons.

Authors:  Dayong Wang; Eunice Y Yuen; Yuan Zhou; Zhen Yan; Yang K Xiang
Journal:  J Biol Chem       Date:  2011-07-11       Impact factor: 5.157

4.  Diet intervention and cerebrospinal fluid biomarkers in amnestic mild cognitive impairment.

Authors:  Jennifer L Bayer-Carter; Pattie S Green; Thomas J Montine; Brian VanFossen; Laura D Baker; G Stennis Watson; Laura M Bonner; Maureen Callaghan; James B Leverenz; Brooke K Walter; Elaine Tsai; Stephen R Plymate; Nadia Postupna; Charles W Wilkinson; Jing Zhang; Johanna Lampe; Steven E Kahn; Suzanne Craft
Journal:  Arch Neurol       Date:  2011-06

5.  Neuronal exosomes reveal Alzheimer's disease biomarkers in Down syndrome.

Authors:  Eric D Hamlett; Edward J Goetzl; Aurélie Ledreux; Vitaly Vasilevko; Heather A Boger; Angela LaRosa; David Clark; Steven L Carroll; María Carmona-Iragui; Juan Fortea; Elliott J Mufson; Marwan Sabbagh; Abdul H Mohammed; Dean Hartley; Eric Doran; Ira T Lott; Ann-Charlotte Granholm
Journal:  Alzheimers Dement       Date:  2016-10-15       Impact factor: 21.566

6.  Binding of amyloid beta peptide to beta2 adrenergic receptor induces PKA-dependent AMPA receptor hyperactivity.

Authors:  Dayong Wang; G Govindaiah; Ruijie Liu; Vania De Arcangelis; Charles L Cox; Yang K Xiang
Journal:  FASEB J       Date:  2010-04-15       Impact factor: 5.191

Review 7.  It's complicated: The relationship between sleep and Alzheimer's disease in humans.

Authors:  Brendan P Lucey
Journal:  Neurobiol Dis       Date:  2020-07-29       Impact factor: 5.996

8.  Plasma beta-amyloid and duration of Alzheimer's disease in adults with Down syndrome.

Authors:  V P Prasher; S G Sajith; P Mehta; W B Zigman; N Schupf
Journal:  Int J Geriatr Psychiatry       Date:  2010-02       Impact factor: 3.485

Review 9.  Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology.

Authors:  Elizabeth Head; Ira T Lott; Donna M Wilcock; Cynthia A Lemere
Journal:  Curr Alzheimer Res       Date:  2016       Impact factor: 3.498

10.  Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease.

Authors:  Anne M Fagan; Chengjie Xiong; Mateusz S Jasielec; Randall J Bateman; Alison M Goate; Tammie L S Benzinger; Bernardino Ghetti; Ralph N Martins; Colin L Masters; Richard Mayeux; John M Ringman; Martin N Rossor; Stephen Salloway; Peter R Schofield; Reisa A Sperling; Daniel Marcus; Nigel J Cairns; Virginia D Buckles; Jack H Ladenson; John C Morris; David M Holtzman
Journal:  Sci Transl Med       Date:  2014-03-05       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.